Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$15.17 USD
-0.09 (-0.59%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $15.09 -0.08 (-0.53%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MESO 15.17 -0.09(-0.59%)
Will MESO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MESO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MESO
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MESO: What are Zacks experts saying now?
Zacks Private Portfolio Services
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
Other News for MESO
12 Health Care Stocks Moving In Friday's Intraday Session
Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday
Mesoblast (MESO) Downgraded by Jefferies to Hold | MESO Stock News
12 Health Care Stocks Moving In Friday's Pre-Market Session
This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday